Long-term predictors of outcome in Brugada syndrome patients after implantable cardioverter-defibrillator implant
Europace · 2026
DOI: 10.1093/europace/euag278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2026. Verfasst von Carlo Napolitano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Pavia, Via Adolfo Ferrata, Pavia 27100, Italy. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Brugada Syndrome, Primary Prevention, Secondary Prevention. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Various clinical risk factors impact the natural history of Brugada syndrome (BrS) and establish the basis of current clinical practice guidelines (CPG) indications for implantable cardioverter-defibrillator (ICD). Due to the time-dependent expressivity of BrS, their performance in predicting the actual occurrence of arrhythmic events after ICD implantation remains unknown.
Objectives
To assess the occurrence of arrhythmic events based on the CPG indications and whether the genetic substrate can add to the prediction of arrhythmic events at follow-up. Methods and results We enrolled consecutive patients who underwent ICD implant either for primary or secondary prevention. Prospective clinical data included arrhythmic history, electrocardiographic findings, therapies, SCN5A gene mutations, and genotyping of three BrS-associated single nucleotide variants. Eleven per cent of 551 patients experienced life-threatening arrhythmic events (LAE) over a median follow-up of 8.1 years. Patients with ESC class IIA indication had a similar risk profile as those implanted for secondary prevention. The recently developed BrS 5-year risk score, including clinical and genetic variables, was a determinant of outcome in the whole cohort and in patients implanted for primary prevention: 26.93 ± 3.33 vs. 4.41 ± 0.61 and 11.67 ± 1.52 vs. 5.36 ± 0.99 in patients with LAEs compared with those without events (P < 0.0001).
Conclusion
CPG class IIa and I had a similar rate of ICD shock at follow-up. We also provide robust evidence indicating that the quantification of the BrS arrhythmic risk score at the moment of ICD implant may improve the identification of patients who will benefit from ICD at follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, University of Pavia, Via Adolfo Ferrata, Pavia 27100, Italy.
- Molecular Cardiology Unit Istituti Clinici Scientifici Maugeri IRCCS, Via Maugeri 10, Pavia 27100, Italy.
- Cardiothoracic Department IRCCS Galeazzi-Sant' Ambrogio, Arrhythmia and Electrophysiology Unit, Milan, Italy.
ORCID-Profile: Carlo Napolitano, Camilla Pizzetti, Deni Kukavica, Massimo Morini, Luca Ottaviano, Mirella Memmi, Patrick Gambelli, Andrea Mazzanti, Alessandro Trancuccio, Gianluca Pili, Silvia G Priori
Zitieren
APA
Napolitano, C., Pizzetti, C., Kukavica, D., Morini, M., Ottaviano, L., Giordano, U., Memmi, M., Gambelli, P., Mazzanti, A., Coppini, L., Trancuccio, A., Pili, G., & Priori, S. G. (2026). Long-term predictors of outcome in Brugada syndrome patients after implantable cardioverter-defibrillator implant. Europace. https://doi.org/10.1093/europace/euag278
Vancouver
Napolitano C, Pizzetti C, Kukavica D, Morini M, Ottaviano L, Giordano U, et al. Long-term predictors of outcome in Brugada syndrome patients after implantable cardioverter-defibrillator implant. Europace. 2026. doi:10.1093/europace/euag278
BibTeX
@article{Napolitano2026,
author = {Napolitano, Carlo and Pizzetti, Camilla and Kukavica, Deni and Morini, Massimo and Ottaviano, Luca and Giordano, Umberto and Memmi, Mirella and Gambelli, Patrick and Mazzanti, Andrea and Coppini, Lucia and Trancuccio, Alessandro and Pili, Gianluca and Priori, Silvia G},
title = {Long-term predictors of outcome in Brugada syndrome patients after implantable cardioverter-defibrillator implant},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag278}
}
EUVIMED